Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

• G. S. Choudhary,
• S. Al-harbi,
• S. Mazumder,
• B. T. Hill,
• M. R. Smith,
• J. Bodo,
• E. D. Hsi,
• A. Almasan

Affiliations

G. S. Choudhary

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

S. Al-harbi

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

S. Mazumder

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic

B. T. Hill

Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic

M. R. Smith

Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic

J. Bodo

Department of Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic

E. D. Hsi

Department of Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic

A. Almasan

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic